Bionik Laboratories Corp.
BNKL
$0.0001
$0.000.00%
03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
---|---|---|---|---|---|
Revenue | 41.72% | -3.22% | -28.44% | -47.39% | 6.74% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 41.72% | -3.22% | -28.44% | -47.39% | 6.74% |
Cost of Revenue | 154.46% | 61.07% | 7.00% | -21.45% | 18.84% |
Gross Profit | 3.84% | -24.88% | -38.80% | -54.29% | 3.19% |
SG&A Expenses | 2.80% | 3.41% | 2.65% | -4.01% | -14.57% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 8.80% | 9.20% | 7.91% | -6.30% | -17.72% |
Operating Income | -0.01% | -13.63% | -20.39% | -6.91% | 22.46% |
Income Before Tax | 52.48% | 45.62% | 4.29% | 5.99% | 23.59% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 52.48% | 45.62% | 4.29% | 5.99% | 23.59% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 52.48% | 45.62% | 4.29% | 5.99% | 23.59% |
EBIT | -0.01% | -13.63% | -20.39% | -6.91% | 22.46% |
EBITDA | -0.85% | -16.62% | -23.49% | -9.08% | 21.72% |
EPS Basic | 59.53% | 51.61% | 17.98% | 19.29% | 33.37% |
Normalized Basic EPS | 27.42% | 8.32% | -3.11% | 2.75% | 23.20% |
EPS Diluted | 59.53% | 51.61% | 17.98% | 19.29% | 33.37% |
Normalized Diluted EPS | 27.42% | 8.32% | -3.11% | 2.75% | 23.20% |
Average Basic Shares Outstanding | 18.45% | 17.25% | 16.95% | 16.14% | 13.65% |
Average Diluted Shares Outstanding | 18.45% | 17.25% | 16.95% | 16.14% | 13.65% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |